Mar 21 |
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
|
Mar 20 |
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
|
Mar 20 |
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
|
Jan 16 |
TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy
|
Dec 5 |
TELA Bio to Take Part in Connecting the Dots
|
Nov 16 |
TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference
|
Nov 13 |
TELA Bio files for $150M mixed shelf
|
Nov 12 |
TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript
|
Nov 12 |
TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript
|
Nov 10 |
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|